Abstract
Breast cancer is the most common malignancy in women worldwide and the most common cause of cancer mortality in women. Seventy percent of breast cancers overexpress the estrogen (ER) and/or the progesterone receptor (PgR) making anti-endocrine therapies the most commonly used worldwide for this disease. These therapies are of low toxicity and low cost since most of them are off-patent and therefore very valuable in the armamentarium against this common form of breast cancer. Selective estrogen receptor modulators (SERMS), selective estrogen receptor down-regulators (SERDS), and aromatase inhibitors (estrogen synthetase) inhibitors (AIs) have been the backbone of recent endocrine treatment of breast cancer. These agents are reviewed here. More recently, combinations of evidence - based targeted therapies with these traditional endocrine therapies have further improved clinical outcomes. In the future, additional agents targeting pathways of resistance to endocrine therapy are likely to be developed.
Keywords: Aromatase inhibitors, breast cancer, endocrine therapy, metastatic, postmenopausal, premenopausal, tamoxifen.
Current Cancer Therapy Reviews
Title:Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer
Volume: 12 Issue: 1
Author(s): Diego Touya, Kathrin Strasser-Weippl, Ann Whalen, Jessica St. Louis and Paul Goss
Affiliation:
Keywords: Aromatase inhibitors, breast cancer, endocrine therapy, metastatic, postmenopausal, premenopausal, tamoxifen.
Abstract: Breast cancer is the most common malignancy in women worldwide and the most common cause of cancer mortality in women. Seventy percent of breast cancers overexpress the estrogen (ER) and/or the progesterone receptor (PgR) making anti-endocrine therapies the most commonly used worldwide for this disease. These therapies are of low toxicity and low cost since most of them are off-patent and therefore very valuable in the armamentarium against this common form of breast cancer. Selective estrogen receptor modulators (SERMS), selective estrogen receptor down-regulators (SERDS), and aromatase inhibitors (estrogen synthetase) inhibitors (AIs) have been the backbone of recent endocrine treatment of breast cancer. These agents are reviewed here. More recently, combinations of evidence - based targeted therapies with these traditional endocrine therapies have further improved clinical outcomes. In the future, additional agents targeting pathways of resistance to endocrine therapy are likely to be developed.
Export Options
About this article
Cite this article as:
Touya Diego, Strasser-Weippl Kathrin, Whalen Ann, Louis St. Jessica and Goss Paul, Emerging Endocrine Therapies in the Treatment of HR-Positive Metastatic Breast Cancer, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160617081058
DOI https://dx.doi.org/10.2174/1573394712666160617081058 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Steroids and the Endometrium
Current Medicinal Chemistry Phytochemicals Resveratrol and Sulforaphane as Potential Agents for Enhancing the Anti-Tumor Activities of Conventional Cancer Therapies
Current Pharmaceutical Biotechnology Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design Synthesis and In Vitro Antitumor Activity of Novel Fluorine Containing Pyrazoles and Pyrazolines
Letters in Drug Design & Discovery ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Imaging Strategies for Rectal Cancer Initial Staging: Does Pelvic Computed Tomography Provide Significantly Additional Findings when High-resolution Magnetic Resonance Imaging has Been Performed?
Current Medical Imaging The Epigenomic Viewpoint on Cellular Differentiation of Myeloid Progenitor Cells as it Pertains to Leukemogenesis
Current Genomics Targeting the Viral Nucleocapsid Protein in Anti-HIV-1 Therapy
Mini-Reviews in Medicinal Chemistry Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Natural Products and their Analogues as Efficient Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases
Current Pharmacogenomics Combination of Histone Deacetylase Inhibitor with Cu(II) 5,5-diethylbarbiturate Complex Induces Apoptosis in Breast Cancer Stem Cells: A Promising Novel Approach
Anti-Cancer Agents in Medicinal Chemistry Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets